University of Zurich

uzh.ch

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

1,040

Active

120

Phase 3

42

Total enrollment

624,148

Pipeline matrix

Showing 20 of 20 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Bryophyllum2
Supplemental oxygen therapy1
Oxygen5
Temozolomide2
Ruxolitinib Topical Cream1
Propranolol1
ALUTARD SQ® Felis domesticus1
Pembrolizumab1
Tideglusib1
Vortioxetine1
50% N2O plus 50% O21
Control Group1
Gabapentin1
Sulfasalazine1
Memantine1
Sevoflurane9
intrathecal nivolumab and intrathecal ipilimumab1
Intranasal ketamine hydrochloride1
Fecal Microbiota Transplantation1
¹⁸F-florbetaben1

Next readouts

  • 2025-12
  • 2025-12
  • 2025-12-01
  • 2026-04-22
  • 2026-04-30
  • 2026-06
  • 2026-07-31
  • 2026-09-30
  • 2027-02
  • 2027-05-31

Top conditions

  • Healthy31
  • Pulmonary Hypertension24
  • Stroke17
  • High Altitude Pulmonary Hypertension16
  • Chronic Obstructive Pulmonary Disease16
  • Glaucoma14
  • Spinal Cord Injury11
  • Coronary Artery Disease10

Frequently asked questions about University of Zurich

How many clinical trials does University of Zurich have on ClinicalTrials.gov?
University of Zurich is listed as the lead sponsor on 1,040 clinical trials in ClinicalTrials.gov, 120 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Zurich's trials are in Phase 3?
42 of University of Zurich's trials are in Phase 3, spread across 20 active drug programs.
What therapeutic areas does University of Zurich focus on?
University of Zurich's most-studied conditions on ClinicalTrials.gov are Healthy, Pulmonary Hypertension, Stroke, High Altitude Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease.
When are University of Zurich's next clinical trial readouts?
University of Zurich has 10 upcoming primary-completion readouts tracked here; the soonest is “Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients”, expected around 2025-12.